CPT1α inhibition reduces long-chain fatty acid (LCFA) transport into and oxidation in muscle mitochondria resulting in an increase in FFA levels (McGarry, 2002), thus potentially contributing to the dyslipidemia observed in our model (Sanghez et al., 2013). The gene discussed is CPT1A; the disease is metabolic syndrome.